Veraxa Biotech AG - Post de-SPAC VRXA
NASDAQ VRXA
$1.00 -0.03 (-2.91%)
At close: Oct 23, 2026 · 4:00 PM EDT

Veraxa Biotech AG - Post de-SPAC (VRXA) Ending Cash Balance (2024 - 2025)

Updated

Analysis

Veraxa Biotech AG - Post de-SPAC (VRXA) Ending Cash Balance (2024 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Ending Cash Balance (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 8.95 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 16.91 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 6.57 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 6.89 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 7.62 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 4.88 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 13.99 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 3.18 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 1.03 Bn
10 Veraxa Biotech AG - Post de-SPAC 14.47 Mn 10.90 Mn - 2.04 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.04 Mn
Dec 31, 2024 5.94 Mn
API Access

Veraxa Biotech AG - Post de-SPAC Ending Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ending-cash-balance&ticker=VRXA&period=max&api_key=YOUR_API_KEY